Search Follow us

BioLight Life Sciences (BOLT)

Business description

Based in Israel, BioLight is an emerging ophthalmic company focused on the development and commercialisation of products and product candidates that address ocular conditions. Lead products IOPtiMate and VS-101 are directed towards the treatment of glaucoma.

Stock data

Market cap.NIS64m
Last closeNIS14.08
High / Low (52 weeks)NIS15.4 / NIS11.0
Stock market listingTel Aviv Stock Exchange
Forecast net cash (NISm)34.2
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.8)(0.1)(3.5)
Relative *(2.1)1.9(11)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
ADL Bionatur Solutions Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Antibe Therapeutics Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT Biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Auris Medical Holding
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Avivagen Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLargo BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma BioPorto Diagnostics
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics Brighter
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Circassia Pharmaceuticals Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Ergomed
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Expedeon
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InflaRx InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medicure
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MGC Pharmaceuticals Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncology Venture Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
OSE Immunotherapeutics Ossur
OvaScience OWL
Oxford BioMedica Oxford Immunotec
Pacific Edge Paion
Paladin Labs Patheon
PBKM PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shield Therapeutics
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics True Leaf
TruScreen TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma ...

Mon, 24 Jul 2017 15:00:00 GMT

BioLight Life Sciences Investments Ltd and Aerie Pharmaceuticals Affiliates ...

Tue, 06 Nov 2012 19:30:00 GMT

BioLight's TeaRx Multi-Parameter Diagnostic Assays to be Used in Dry Eye ...

Thu, 23 Feb 2017 12:04:26 GMT

BioLight Announces Partnership With Axella Research For CellDetect® Non ...

Mon, 30 Nov 2015 12:00:00 GMT

Biolight Life Sciences: Ioptima Divestiture Now In Progress

Tue, 24 Apr 2018 08:26:15 GMT

Y/E Dec Revenue (NISm) EBITDA (NISm) PBT (NISm) EPS (NIS) P/E (x) P/CF (x)
2016A 2.1 (20.2) (26.3) (5.37) N/A N/A
2017A 1.2 (26.8) (26.6) (5.29) N/A N/A
2018E 0.9 (24.0) (26.3) (5.21) N/A N/A
2019E 0.9 (24.4) (26.3) (5.56) N/A N/A

Last updated on 20/11/2018

Latest research

המחקר העדכני ביותר

ביולייט מדעי החיים

ביולייט מדעי החיים בע"מ: תמורת הנפקת הזכויות מהווה מימון מספק לפחות עד קבלת התמורה הראשונה מעסקת מכירת איי אופטימה

09/07/2018
ביולייט מדעי החיים

IOPtima הסכם סופי ומחייב להשקעה ולמכירת

24/04/2018
ביולייט מדעי החיים

IOPtima הסכם סופי ומחייב להשקעה ולמכירת

28/11/2017
ביולייט מדעי החיים

בעקבות הקפאת ההפצה באסיה IOPtima האטה במכירות

12/09/2017
ביולייט מדעי החיים

ביולייט מדעי החיים בע"מ - הפרסום האחרון מדגיש את בטיחותה היחסית של IOPtiMate

22/12/2016
ביולייט מדעי החיים

ביולייט מדעי החיים בע"מ

19/10/2016

Investment summary

BioLight Life Sciences is developing Eye-D VS-101, an extended-dose latanoprost drug implant designed to treat glaucoma (and had positive data in a Phase I/IIa trial) and TeaRx, a dry-eye syndrome diagnostic test. VS-101 can be helpful for the 20-60% of glaucoma patients who do not comply with daily eye-drop therapy.

Last updated on 29/11/2018

Industry outlook

BioLight's IOPtima subsidiary signed an agreement in Q417 to be acquired by Chengdu Kanghong Pharma in a four-stage transaction. The gross proceeds to BioLight for its stake should range between $23m and $27m (by mid-2021). BioLight reported in September 2018 that it received c $12m for the sale of roughly half of its IOPtima stake to Chengdu. Chengdu now holds 60% of IOPtima and BioLight now holds 26%. BioLight raised NIS11.4m in May 2018 through the issuance of 908,540 shares.

Last updated on 29/11/2018

Key management

Israel Makov, Chairman
Suzana Nahum Zilberberg, CEO
Itai Bar-Natan, CFO

Company address

Kiryat Atidim Building 3
5th Floor
Tel Aviv
6158101
Israel
972-73-2753400
View website